

# Transplantation of Mesenchymal Stem Cells in Treating Patients with Severe COVID-19: A Systematic Review and Meta-Analysis

Attapon Cheepsattayakorn<sup>1,2\*</sup> and Ruangrong Cheepsattayakorn<sup>3</sup>

<sup>1</sup>10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

<sup>2</sup>Faculty of Public Health, St. Theresa International College, Nakhon Nayok, Thailand

<sup>3</sup>Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

## \*Corresponding author

Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road, Changklan, Muang, Chiang Mai, 50100, Thailand

Submitted: 09 May 2020; Accepted: 19 May 2020; Published: 05 Jun 2020

## Abstract

The objective of the study is to perform a critical review, exploration, and strong summary of the roles of mesenchymal stem cell transplantation in treating various diseases, including COVID-19. A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including Scien Direct, PubMed, Scopus, ISI Web of Science, and websites of the news. The search was applied to the articles that were published between January 2020 and April 2020. Needed article information was extracted from each article by : 1) direct information including journal (research article, review article, meeting abstract, conference abstract, correspondence, author index, editorial board meeting abstract, discussion), book chapter, title, authors, abstract, full text documents of candidate studies, websites of the news, publishing year; 2) study period; 3) research (study) method used; 4) types of mesenchymal stem cells; and 5) types of human organ system disorder or disease studied. With strict literature search and screening processes, it yielded 6 articles from 76 articles of initial literature databases and websites of the news (January 2020 to April 2020). Anti-inflammatory and immunomodulatory properties of MSCs in the treatment of respiratory diseases were confirmed by at least 17 clinical studies and more than 70 clinical trials are registered in this issue that are available at: <https://www.clinicaltrials.gov>. MSC transplantation improves the treatment outcome of COVID-19 patients may be due to controlling inflammatory response and promoting tissue regeneration and repair. In conclusion, Human MSCs are currently being evaluated as a stem cell treatment for a number of diseases, particularly severe COVID-19 and have been demonstrated to be safe in clinical trials. There are some promising reports to apply MSCs therapy to treat COVID-19. MSCs may possibly be one of the most ideal therapeutics, or a combination of treatment to treat patients with COVID-19. Nevertheless, further studies are urgently needed to investigate and optimize a number of variables in the human MSC culture environment by developing a bioprocess that can be operated in accordance with the Good Manufacturing Product (GMP).

**Keywords:** Acute Respiratory Distress Syndrome, COVID-19, Novel Coronavirus-2019, Mesenchymal, Pneumonia, Stem Cell, SARS-CoV-2, Severe, Transplantation

## Abbreviations

ACE 2 : Angiotensin-Converting Enzyme 2  
AF : Amniotic Fluid  
ALT : Alanine Transaminase  
Ang-1 : Angiopoietin-1  
ARDS : Acute Respiratory Distress Syndrome  
AST : Aspartate Transaminase  
AT : Adipose Tissue  
BALF : Broncho Alveolar Lavage Fluid  
BM : Bone Marrow  
CFU-F : Colony-Forming Unit Fibroblast  
CIK : Cytokine-Induced Killer Cells  
CM : Conditioned Media  
COVID-19 : Coronavirus Disease 2019  
CRP : C-reactive protein

CT : Computed Tomography  
CTL : Cytotoxic T Cells  
DC : Dendritic Cell  
DP : Dental Pulp  
EVs : Extracellular Vesicles  
FiO<sub>2</sub> : Fraction of Inspiration Oxygen  
G-CSF : Granulocyte-Colony-Stimulating Factor  
GVHD : Graft-Versus-Host Disease  
HGF : Hepatocyte Growth Factor  
HLA : Human Leukocyte Antigen  
ICU : Intensive Care Unit  
IFITM : Interferon-Induced Transmembrane Protein  
IFN- $\alpha$  : Interferon-Alpha  
IFN- $\gamma$  : Interferon-Gamma  
IL : Interleukin  
IP : Interferon Gamma-Induced Protein  
ISG : Interferon-Stimulated Gene  
KGF : Keratinocyte Growth Factor  
MCP : Monocyte Chemoattractant Protein

MIP	: Macrophage Inflammatory Protein
MSCs	: Mesenchymal Stem Cells
NK	: Natural Killer Cells
PaO <sub>2</sub>	: Arterial Partial Pressure of Oxygen
PB	: Peripheral Blood
PL	: Placenta
RT-PCR	: Reverse Transcriptase-Polymerase Chain Reaction
SARS-CoV-2	: Severe Acute Respiratory Syndrome Coronavirus-2
SF-36	: 36 Item Short-Form Health Survey
TGF-β	: Transforming Growth Factor-Beta
TMPRSS2	: Type II Transmembrane Serine Protease
TNF-α	: Tumor Necrosis Factor-Alpha
UC	: Umbilical Cord
UCB	: Umbilical Cord Blood
WJ	: Warton Jelly

## Introduction

*In vitro*, mesenchymal stem cell (MSC) populations with potentials of similar multi-lineage differentiation have been obtained from several bone marrow (BM) and non-bone marrow tissues, including umbilical cord, placenta, amniotic fluid, adipose tissue, and peripheral blood [1-10]. The clonogenic BM-human MSCs fraction ranges from 10 to 100 colony-forming unit-fibroblast (CFU-F) per 10<sup>6</sup> marrow mononuclear cells (MNCs) [11]. BM-human MSCs are characterized by lacking CD11b, CD14, CD19, CD34, CD45, CD79 $\alpha$ , and human leukocyte antigen (HLA)-DR expression; positive expression of surface antigens CD73, CD90, and CD105; multipotency (i.e., chondrogenic, osteogenic, and adipogenic); and their adherence to plastic [11]. By the year 2000, clinicians increasingly had become interested in intravenously applied MSC therapy [12]. A previous study demonstrated that both human and murine MSCs can induce immune suppression by attracting and killing autoreactive T cells via FasL, therefore stimulating transforming growth factor-beta (TGF- $\beta$ ) production by macrophages and generation of regulatory T cells [13]. The dying T cells that is caused by the interaction involving the MSC-induced Monocyte Chemoattractant Protein-1 (MCP-1) secretion in turn activate macrophages to produce TGF- $\beta$ , then stimulating regulatory T cells and promoting immune tolerance [14]. The capacity of MSCs for *in vivo* differentiation and engraftment and by their efficacy in promoting wound healing highlighted its clinical relevance [15-21].

In 2006, the International Society for Cellular Therapy came up with the guidelines for MSC characterization for standardization the MSC biology, definition, isolation, and characterization criteria, *in vivo* relevance, and ethical and institutional regulations for its clinical use [11]. Since the COVID-19 pandemic, there are several ongoing trials that have been studied in China, such as the Clinical Trials. Gov identifiers: NCT04252118, NCT04273646, NCT04276987, NCT04293692, NCT04302519, NCT04288102, etc. For fighting against severe COVID-19 or COVID-19 pneumonia [22-27]. MSCs can decrease the overproduction of immune cells caused by a reaction to the COVID-19 and decrease excessive levels of inflammatory substances, contributing to regulating the immune system and recovering to the normal status, particularly of the elderly patients [28].

## Methods of the Study

### Search Strategy and Inclusion Criteria

A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including ScienDirect,

PubMed, Scopus, ISI Web of Science, and websites of the news. The search was applied to the articles that were published between January 2020 and April 2020. Our first involved performing searches of article abstract/keywords/title using strings of [(“COVID-19” or “novel coronavirus-2019”, or “SARS-CoV-2”, “immune disorders or diseases” or “autoimmune disorders or diseases”, “acute respiratory distress syndrome” or “acute respiratory distress syndrome-related COVID-19 or “acute respiratory distress syndrome-related novel coronavirus-2019”, “pneumonia” or “pneumonia-related COVID-19”, or “pneumonia-related novel coronavirus-2019”, “novel therapeutics on “COVID-19” or “novel coronavirus-2019” or SARS-CoV-2”)]. After a first approach of search, published articles focusing on transplantation of mesenchymal stem cells in treating COVID-19 or novel coronavirus-2019 were retained and the information on “COVID-19” or “novel coronavirus-2019”, or “SARS-CoV-2”, “immune disorders or diseases” or “autoimmune disorders or diseases”, “pneumonia” or “pneumonia-related diseases”, “novel therapeutics on “COVID-19” or “novel coronavirus-2019” or “SARS-CoV-2” was extracted for having a crude knowledge involving their themes. Another round of publication search was conducted for adding the missing published articles that were not identified by the first round.

All keywords combinations from “ COVID-19 ” or “ novel coronavirus-2019 ”, or “ SARS-CoV-2 ”, “ immune disorders or diseases ” or “ autoimmune disorders or diseases ”, “ pneumonia ” or “ pneumonia-related diseases ”, “ novel therapeutics on “ COVID-19 ” or “ novel coronavirus-2019 ” or “ SARS-CoV-2 ” to bind the population of cases under consideration. Search string for disease groups include [(“ COVID-19 ” or “ novel coronavirus-2019 ”, “ immune disorders or diseases ” or “ autoimmune disorders or diseases ”, “ pneumonia ” or “ pneumonia-related diseases ”, “ novel therapeutics on “ COVID-19 ” or “ novel coronavirus-2019 ”, or “ SARS-CoV-2 ” )]. The initial literature databases were further manually screened with the following rules: 1) non-COVID-19-, non-novel coronavirus-2019-, and non-SARS-CoV-2-related articles were excluded; 2) articles that did not report mesenchymal stem cell transplantation on COVID-19 or novel coronavirus-2019 or SARS-CoV-2 were not considered, such as commentary articles, or editorial; 3) non-peer reviewed articles were not considered to be of a scholarly trustworthy validity; and 4) duplicated and non-English articles were removed. The articles were carefully selected to guarantee the literature quality, which is a trade-off for quantity.

## Results

With strict literature search and screening processes, it yielded 6 articles from 76 articles of initial literature database and websites of the news (January 2020 to April 2020). Needed article information was extracted from each article by : 1) direct information including journal, (research article, review article, meeting abstract, conference abstract, correspondence, author index, editorial board meeting abstract, discussion), book chapter, title, authors, abstract, full text documents of candidate studies, websites of the news, publishing year; 2) study period; 3) research (study) method used; 4) types of mesenchymal stem cell variables studied in transplantation; 5) types of organ system disorder or disease studied; and 6) the conclusions made about the mesenchymal stem cell transplantation in treating COVID-19 or novel coronavirus-2019 or SARS-CoV-2. An overview of the


information required for the present analysis that was captured by those themes was shown in the Figure 1. Results from 6 yielded articles (Reference number to Reference number) was demonstrated in the (Figure 1, Table 1).

**Table 1:** Demonstrating article contents of mesenchymal stem cell transplantation in treating COVID-19 and references published between January 2020 and April 2020

Published Year	Article Content	Reference
2020	Clinical trial ID (Registry) : 1) NCT04293692 (ClinicalTrials.gov, umbilical cord MSCs, randomized, triple blinded, withdrawn, China); 2) NCT04273646 (ClinicalTrials.gov, umbilical cord MSCs, randomized, non-blinded, not recruiting, China); 3) NCT04269525 (ClinicalTrials.gov, umbilical cord MSCs, non-randomized, non-blinded, recruiting, China); 4) ChiCTR2000030138 (ICTPR, umbilical cord MSCs, randomized, double blinded, not recruiting, China); 5) ChiCTR2000030484 (ICTPR, umbilical cord MSCs and derived exosomes, unspecified randomized, unspecified blinded, not recruiting, China); 6) ChiCTR2000030116 (ICTPR, umbilical cord MSCs, randomized, unspecified blinded, recruiting, China); 7) ChiCTR2000029816 (ICTPR, umbilical cord MSCs, randomized, non-blinded, not recruiting, China); 8) NCT04313322 (ClinicalTrials.gov, Wharton jelly MSCs, non-randomized, non-blinded, recruiting, Jordan); and 9) ChiCTR2000030088 (ICTPR, Wharton jelly MSCs, randomized, unspecified blinded, not recruiting, China)	29
2020	Human umbilical cord MSCs effectively modulated the immune response and repaired injured tissues of critically ill COVID-19 patient with excellent safety by intravenous route three times (5 X 10 <sup>7</sup> cells each time) every three days. After second administration, the vital signs were improved, the tracheal tube was pulled off and the serum C-reactive protein (CRP), serum alanine transaminase/aspartate transaminase (ALT/AST), and serum bilirubin were gradually decreased. MSC significantly improved the pulmonary function and clinical symptoms of patients with COVID-pneumonia.	30
2020	MSC transplantation in patients with influenza A (H <sub>7</sub> N <sub>9</sub> ) infection induced ARDS were conducted in a single center and open-label clinical trial. Several parameters, such as computed tomography of the chest (1 week, 1 months, 6 months, and 12 months), pulmonary ventilatory function (6 months and 12 months), 36 Item Short-Form Health Survey (SF-36) (Chinese version) of the Medical Outcome Study (Health-Related Quality of Life (HRQoL) (6 months and 12 months) after MSC transplantation. MSCs have ability to decrease inflammatory effects and defend against cytokine storm. MSCs probably decrease the secretions of the inflammatory factors. MSCs significantly decreased the mortality (16.7 % in MSC group versus 54.5 % in control group). No serious adverse effects are identified after MSC transplantation during the period of 5 years. Nevertheless, long-term pulmonary dysfunction is still a problem after 2 years of hospital discharge.	31
2020	In animal models, H <sub>5</sub> N <sub>2</sub> viral infection increases serum and pulmonary chemokines responsible for pulmonary leukocyte infiltration. Antiviral protein members of the IFITM family members are unique as they prevent infection before a virus can traverse the lipid bilayer of the cell contributing the limitation of infection in cultured cells by many viruses, such as SARS coronavirus, influenza A virus, Ebola virus, dengue virus, etc., whereas knockdown of IFITM3 rendered MSC susceptible to infection by a variety of viruses, such as Zika virus, Yellow Fever virus, etc. Pro-inflammatory cytokines including IFN-γ induced non-constitutive ISGs including CD74, IFNAR2, MT1G, MT1X, SAT1, SERPING1, whereas significantly increasing the expression of constitutive antiviral genes, such as CCL2, IFI6, IFITM1, ISG15, PMAIP1, and SAT1. In a respiratory viral infection including COVID-19, MSCs might present two distinct antiviral mechanisms : 1) constitutively elevated the levels of MSC-specific ISGs to function as mediators of an antiviral protection, and 2) a secondary response to IFN, contributing to ISG induction and broad viral resistance. MSCs could present a mix of inducible and intrinsic innate antiviral defenses that could contribute to treatment benefits in severe COVID-19 patients. BM-MSCs are permissive to avian influenza A (H <sub>5</sub> N <sub>1</sub> ) infection, losing immunoregulatory activities, and viability. Virus-infected MSCs may not be functionally effective at stopping virus replication and pulmonary injury. BM-MSCs and UC-MSCs were more effective than adipose tissue-derived MSCs in decreasing mortality in pre-clinical acute lung injury models (rodents, pig, sheep, and explanted human lungs). Neither synergistic or xenogeneic MSC administration, either alone or as an adjuvant therapy with oseltamivir was effective either when administered prophylactically, prior to H <sub>5</sub> N <sub>1</sub> virus inoculation, or when therapeutically administered, similar to the results of both systemic and intratracheal administration of human and mouse MSCs. MSCs did not improve influenza-mediated lung injury regardless of administration route. Avian influenza-virus infection can trigger a very intense pro-inflammatory response compared to other influenza virus, thus the beneficial effects might be a specific consequence of different pathogenic features as compared to swine-origin H <sub>1</sub> N <sub>1</sub> infection. In vitro airway epithelial cell models and experimental lung injury induced by Influenza A (H <sub>3</sub> N <sub>2</sub> ) infection in female mice, UC-MSCs were more effective than human BM-MSCs at restoring impaired alveolar fluid clearance and permeability. MSCs-derived EVs were more effective than MSCs themselves in some H <sub>5</sub> N <sub>1</sub> cases inflammation and injury of the lungs in pre-clinical lung injury models, particularly EVs isolated from pig BM-derived MSCs in reducing virus shedding in nasal swabs, influenza replication in the lungs, BALF pro-inflammatory cytokines and chemokines, and histopathologic changes in a mixed swine (H <sub>3</sub> N <sub>2</sub> , H <sub>1</sub> N <sub>1</sub> ) and avian (H <sub>9</sub> N <sub>5</sub> , H <sub>7</sub> N <sub>2</sub> ) influenza-induced pig lung injury model after 12 hours of administration. Clinical improvement within 2-4 days after MSC administration was observed in a patient with critically severe COVID-19. The intravenous dosing range of MSCs varies between 0.4 and 42 X 10 <sup>6</sup> cells/kg. The highest dose of MSCs used in non-viral ARDS was 10 X 10 <sup>6</sup> cells/kg (START trial). The MSC dosing strategy ranged between a single and 5 doses with an average frequency of every 2 days.	32
2020	Seven patients with COVID-19 pneumonia were enrolled and evaluation of the outcomes for MSC transplantation after 14 days of MSCs injection (January 23, 2020-February 16, 2020). The pulmonary function (one million MSCs per kilogram body weight) and symptoms of all 7 patients were significantly improved without observed adverse effects within 2 days after MSC injection. One severe and two common COVID-19 patients were recovered and discharged in 10 days after MSC treatment. After MSC transplantation, the CRP decreased, peripheral lymphocytes increased, and the overactivated cytokine-secreting immune cells (CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells) disappeared in 3-6 days. CD14+CD11c+CD11b <sup>mid</sup> regulatory DC cell population increased. TNF-α level was significantly reduced. IL-10 level increased. The cytokine storm was dramatically improved in one patient with critically severe COVID-19 in 2-4 days after MSCs injection. MSCs were free from COVID-19 infection by demonstration of ACE2 and TMPRSS2 in gene expression profile.	33



Much superiority in using MSC treatment in comparison with other treatment modalities includes : 1) easily accessible and can be isolated from various tissues (BM, AT, UC, buccal fat pad, fetal liver, menstrual blood, etc.), 2) are multipotent stem cells, 3) MSCs can be stored for repetitive therapeutic usage, 4) MSCs can easily expand to clinical volume in a proper period of time, 5) clinical trials of MSCs have not demonstrated adverse side effects or reactions to allogeneic MSC, and 6) several clinical trials demonstrated safety and effectiveness of MSCs. MSC treatment probably can prevent the cytokine storm releasing by the immune system and promote endogenous repair by reparative properties of the MSCs. MSCs could protect pulmonary alveolar epithelial cells, recover the pulmonary microenvironment, intercept pulmonary fibrosis, and cure pulmonary dysfunction and COVID-19 pneumonia. MSCs can be isolated from BM, PB, AT, PL, UC, WJ, AF, UCB, and neonatal birth-associated tissues. MSC transplantation is also widely used in the treatment of graft-versus-host disease (GVHD), spinal cord injury, autoimmune disease, type 2 diabetes mellitus, and other high immunity diseases. Second and third intravenous injections of UC-MSCs in combination with lopinavir/ritonavir,  $\alpha$ 1-thymosin, IFN- $\alpha$ , and oseltamivir as well as intravenous injection of immunoglobulin, methylprednisolone, Xuebijing, and moxifloxacin in a 65-year-old female patient with critically ill COVID-19 demonstrated the improvement of COVID-19 pneumonia 2 days after the third injection of MSCs.



**Figure 1:** Literature Search and Screening Flow

## Discussion

Currently, there are no approved therapeutic options for either the prevention or treatment of COVID-19 [29]. MSCs act via a paracrine mechanism [30]. They release biological active substances “secretome” that is made of both growth factors and extracellular vesicles (EVs) and soluble proteins, including a broad

spectrum of chemokines and cytokines [31]. EVs are also described as mediating the protective effects of MSCs in pre-clinical models of bacteria and non-infectious acute pulmonary injury [32]. Additionally, MSCs can secrete angiopoietin-1 (Ang-1), keratinocyte growth factor (KGF), and hepatocyte growth factor (HGF) that contribute to the restoration of alveolar-capillary barriers disrupted as part of ARDS pathogenesis [32]. Releasing soluble proteins and EVs interact with the target cells by internalization or ligand-receptor interaction. MSC-secretome acts on several cytokines potentially, simultaneously, and synergistically [30]. MSC-secretome can activate endogenous stem cells, and progenitor cells, regulate the inflammatory response, stimulate angiogenesis and remodeling of the extracellular matrix, suppress apoptosis, mediate chemoattraction, and reduce fibrosis [30]. Nevertheless, mediators responsible for ameliorating respiratory viral-induced lung injury remain unclear [32]. One of the two distinct antiviral mechanisms of the MSCs is the constitutively elevated levels of MSC-specific interferon-stimulated genes (ISGs) to function as mediators of an antiviral protection [32]. The effectiveness of MSC-secretome on autoimmune diseases and ARDS is evidenced, both *in vivo* and *ex vivo*. Secretome with highly stability in the blood circulation spread into tissues, particularly lungs and provide immune modulation, restoration of capillary barrier function, resolution of inflammation, and enhance bacterial clearance [30]. Generally, secretome is considered safer than MSCs due to low immunogenicity, low emboli formation, and lacking the potential for endogenous tumor formation [30] in treating COVID-19, virus-induced ARDS and other viral disease, such as H<sub>2</sub>N<sub>9</sub>-severe lung disease [30, 31]. With fewer costs and ready-to-use product, MSC-secretome treatment seems to be technological advantages [30].

Very recently, MSC-secretome can be formulated as both injectable dosage forms and inhalable dosage form. MSC-secretome therapy emerges as a promising cell-free treatment modality for both acute and chronic pulmonary diseases [30]. Recently, two Chinese clinical trials, NCT04276987 (inhaled secretome for the treatment of critically ill COVID-19 pneumonia) and NCT04313647 (secretome tolerance in healthy volunteers) appeared on the URL: <http://www.clinicaltrials.gov> [30]. A previous report from China revealed that the levels of serum IL-2, IL-7, G-SCF, IP-10, MCP-1, MIP-1 A, and TNF- $\alpha$  in ICU-COVID-19 patient were higher than those of non-ICU-COVID-19 patients [33]. Nevertheless, there are only a small number of pre-clinical investigations on effects of MSC administration in pre-clinical models of respiratory virus infections and there yet no pre-clinical data investigating the effects of MSC administration in the models of coronavirus respiratory infection, mostly due to lacking an established animal model [32].

A previous study on both human and mouse MSCs administration demonstrated that MSCs did not improve influenza (H<sub>1</sub>N<sub>1</sub>)-mediated pulmonary injury regardless of administration route [32]. Nevertheless, there are evidence-based studies that MSC therapy can inhibit the over activation of the immune system and promote endogenous repair by improving the microenvironment [33]. At least 4 of the trials will utilize either MSC-derived conditioned media (CM) or EVs. Two of these propose aerosol inhalation of MSC-derived EVs, one from adipose-derived MSCs, for which there is no pre-clinical supporting data. Six studies will utilize other cells including UCB-derived mononuclear cells, cytotoxic T cells (CTL), dendritic cells (DC), natural killer cells (NK), umbilical cord blood stem cells (UCB-SC), or cytokine-induced killer cells (CIK). Only the latter study describes dosing and frequency of MSC injections [32]. Apparent pre-clinical data are not available to support the rationale for any of these therapeutic interventions. More pre-clinical data involving the models of coronavirus-induced pulmonary injuries are needed to initiate trials of MSC-based studies with highest standards for rationale and properly designed investigations. These are the only ways that a rationale evidence-based framework for potential cell-based therapies can be developed [32]. A recent study of 7 COVID-19 patients in China (one with critical severe type, 4 with severe type, and the other 2 with common type of COVID-19 syndrome) were received 1 million MSCs per kilogram body weight and were closely observed their symptoms for 14 days. This study revealed that all symptoms disappeared by 2-4 days after MSCs intravenous administration with no apparent adverse effects [32-34]. The majority of patients demonstrated negative results of the reverse transcriptase polymerase chain reaction (RT-PCR) tests for COVID-19 or SARS-CoV-2 or novel coronavirus-2019 nucleic acid over a week or two weeks as well as the significant resolution of pneumonic infiltration in the chest computed tomographic (CT) imaging after MSC intravenous administration [32-34]. The National Health Commission of China classifies the clinical grading of the COVID-19 as the following: 1) Mild type-mild clinical manifestation, none imaging performance, 2) Common type-fever, respiratory symptoms, pneumonia performance on chest X-ray or CT, 3) Severe type-meet any of the followings: 3.1) respiratory distress, respiration rate at least 30/minute, 3.2) oxygen saturation not higher than 93 % at rest state, and 3.3) arterial partial pressure of oxygen (PaO<sub>2</sub>)/fraction of inspiration oxygen (FiO<sub>2</sub>) not higher than 300 mmHg (1 mmHg = 0.133kpa), and 4) critically severe-meet any of the followings: 4.1) respiratory failure needs mechanical ventilation, 4.2) shock, and 4.3) combined with other organ failure, patients need ICU monitoring and treatment [33]. Anti-inflammatory and immunomodulatory properties of MSCs in the treatment of respiratory diseases were confirmed by at least 17 clinical studies and more than 70 clinical trials are registered in this issue that are available at: <https://www.clinicaltrials.gov> [34]. MSC transplantation improves the treatment outcome of COVID-19 patients may be due to controlling inflammatory response and promoting tissue regeneration and repair [33].

## Conclusion

Human MSCs are currently being evaluated as a stem cell treatment for a number of diseases, particularly severe COVID-19 and have been demonstrated to be safe in clinical trials. There are some promising reports to apply MSCs therapy to treat COVID-19. MSCs may possibly be one of the most ideal therapeutics, or a

combination of treatment to treat patients with COVID-19. Nevertheless, further studies are urgently needed to investigate and optimize a number of variables in the human MSC culture environment by developing a bioprocess that can be operated in accordance with the Good Manufacturing Product (GMP).

## Competing Interests

The authors declare that they have no actual or potential competing financial interests. Funding Sources. The authors disclose no funding sources.

## Reference

1. Williams AR, Ha re JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. *Cir Res* 109: 923-940.
2. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, et al. (2004) Isolation of multipotent mesenchymal stem cells from umbilical cord blood. *Blood* 103: 1669-1675.
3. Wang HS, Hung CS, Peng ST, Huang CC, Wei HM, et al. (2004) Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells* 22: 1330-1337.
4. Tondreau T, Meuleman N, Delforge A, Dejenné M, Leroy R, et al. (2005) Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood : proliferation, Oct4 expression, and plasticity. *Stem Cells* 23: 1105-1112.
5. Vellasamy S, Sandrasaigaran P, Vidyadaran S, George E, Ramasamy R (2012) Isolation and characterization of mesenchymal stem cells derived from human placenta tissue. *World J Stem Cells* 4: 53-61.
6. Anker PS, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, et al. (2003) Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. *Blood* 102: 1548-1549.
7. De Coppi P, Bartsch Jr G, Siddiqui MM, Xu T, Santos CC, et al. (2007) Isolation of amniotic stem cell lines with potential for therapy. *Nat Biotechnol* 25: 100-106.
8. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, et al. (2002) Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 13: 4279-4295.
9. Gimble J, Guilak F (2003) Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. *Cytotherapy* 5: 362-369.
10. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, et al. (2000) Mesenchymal precursor cells in the blood of normal individuals. *Arthritis Res* 2: 477-488.
11. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells, the International Society for Cellular Therapy position statement. *Cytotherapy* 8: 315-317.
12. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, et al. (2002) Isolated allogeneic bone marrow-derived mesenchymal cells engraft for cell therapy of bone. *Proc Natl Acad Sci USA* 99: 8932-8937.

13. Akiyama K, Chen C, Wang D, Xu X, Qu C, et al. (2012) Mesenchymal stem cell-induced immunoregulation involves Fas ligand/Fas-mediated T cell apoptosis. *Cell Stem Cell* 10: 544-555.
14. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ (2011) Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-Kb signaling in resident macrophages. *Blood* 118: 330-338.
15. Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details. *Cell Stem Cell* 4: 206-216.
16. Sivanathan KN, Gronthos S, Rojas-Canales D, Thierry B, Coates PT (2014) Interferon-gamma modification of mesenchymal stem cells : implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. *Stem Cell Rev* 10: 351-375.
17. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, et al. (2010) Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. *Proc Natl Acad Sci USA* 107: 5652-5657.
18. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, et al. (2008) Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* 2: 141-150.
19. English K, French A, Wood KJ (2010) Mesenchymal stromal cells: facilitators of successful transplantation? *Cell Stem Cell* 7: 431-442.
20. Murphy MB, Moncivais K, Caplan AI (2013) Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. *Exp Mol Med* 45: e54.
21. Tyndall A (2014) Mesenchymal stem cell treatments in rheumatology: a glass half full? *Nat Rev Rheumatol* 10: 117-124.
22. Beijing 302 Hospital, China. ClinicalTrials.gov Identifier: NCT04252118. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus [https://clinicaltrials.gov/ct2/show/NCT04252118?show\\_xprt=Y](https://clinicaltrials.gov/ct2/show/NCT04252118?show_xprt=Y)
23. Wuhan Union Hospital, China. ClinicalTrials.gov Identifier: NCT04273646. Study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus severe pneumonia. [https://clinicaltrials.gov/ct2/show/NCT04273646?show\\_xcprt=Y](https://clinicaltrials.gov/ct2/show/NCT04273646?show_xcprt=Y)
24. Ruijin Hospital, China. ClinicalTrials.gov Identifier: NCT04276987. A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia [https://clinicaltrials.gov/ct2/show/NCT04276987?show\\_xprt=Y](https://clinicaltrials.gov/ct2/show/NCT04276987?show_xprt=Y)
25. Puren Hospital Affiliated to Wuhan University of Science and Technology, China. ClinicalTrilas.gov Identifier: NCT04293692. Therapy for pneumonia patients infected by 2019 novel coronavirus. [https://clinicaltrials.gov/ct2/show/NCT04293692?show\\_xprt=Y](https://clinicaltrials.gov/ct2/show/NCT04293692?show_xprt=Y)
26. CAR-T (Shanghai) Biotechnology Co., Ltd., China. Clinical Trials.gov Identifier: NCT04302519. Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells [https://clinicaltrials.gov/ct2/show/NCT04302519?show\\_xprt=Y](https://clinicaltrials.gov/ct2/show/NCT04302519?show_xprt=Y)
27. Beijing 302 Hospital, China. ClinicalTrials.gov Identifier: NCT04288102. Treatment with mesenchymal stem cells for severe coronavirus disease 2019 (COVID-19) <https://clinicaltrials.gov/ct2/show/NCT04288102>
28. Liying Z (2020) China.org.cn. Mesenchymal stem cell therapy shows promise in treating COVID-19. [www.china.org.cn/china/2020-03/07/content\\_75785868.html](http://www.china.org.cn/china/2020-03/07/content_75785868.html)
29. Lythgoe MP, Middleton P (2020) Ongoing clinical trials for the management of the COVID-19 pandemic. *Trends in Pharmaceutical Sciences* 2020: PMC7144665.
30. Bari Elia, Ferrarotti I, Saracino L, Perteghella S, Torre ML, et al. (2020) Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. *Cells* 9: 1-6.
31. Chen J, Hu C, Chen L, Tang L, Zhu Y, et al. (2020) Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. *Engineering Journal Pre-proofs S2095-8099: 30037-0*.
32. Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, et al. (2020) Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. *European Respiratory Journal*.
33. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, et al. (2020) Transplantation of ACE 2: mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. *Aging and Disease* 11: 216-228.
34. Golchin A, Seyedjafari E, Ardeshiryajimi A (2020) Mesenchymal stem cell therapy for COVID-19: present and future. *Stem Cell Reviews and Reports* 16: 427-433.

**Copyright:** ©2020 Attapon Cheepsattayakorn, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.